NOVOMIX-30

This brand name is authorized in Austria, Australia, Brazil, Canada, Cyprus, Estonia, Spain, Finland, France, Hong Kong, Ireland, Israel, Lithuania, Nigeria, Netherlands, New Zealand, Poland, Romania, Singapore, Tunisia, Turkey, United Kingdom, South Africa

Active ingredients

The drug NOVOMIX-30 contains one active pharmaceutical ingredient (API):

1 Insulin aspart UNII 978D8U419H - SACCHAROMYCES CEREVISIAE

The blood glucose lowering effect of insulin aspart is due to the facilitated uptake of glucose following binding of insulin to receptors on muscle and fat cells and to the simultaneous inhibition of glucose output from the liver. Insulin aspart produces a more rapid onset of action compared to soluble human insulin, together with a lower glucose concentration, as assessed within the first four hours after a meal. Insulin aspart has a shorter duration of action compared to soluble human insulin after subcutaneous injection. Read about Insulin aspart

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
A10AD05	Insulin aspart	A Alimentary tract and metabolism → A10 Drugs used in diabetes → A10A Insulins and analogues → A10AD Insulins and analogues for injection, intermediate-acting combined with fast-acting
Discover more medicines within A10AD05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 12238D, 8609D
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 526602001159415, 526602002155316
Country: CA	Health Products and Food Branch	Identifier(s): 02265435
Country: EE	Ravimiamet	Identifier(s): 1084788, 1084823, 1214468, 1214479, 1523786
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 00142009, 00142015, 00142021
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 001490, 006024
Country: FR	Base de données publique des médicaments	Identifier(s): 61693569, 64239493, 67832552, 68182431
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 143813, 143865, 201635, 32773, 32781, 376949, 376952, 379926
Country: HK	Department of Health Drug Office	Identifier(s): 52604, 61546
Country: IE	Health Products Regulatory Authority	Identifier(s): 64275, 68927, 68930, 76140
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 4621
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1004366, 1008620, 1029898, 1029899, 1059246, 1059247, 1059248
Country: NG	Registered Drug Product Database	Identifier(s): A6-0204
Country: NL	Z-Index G-Standaard	Identifier(s): 14719509, 14719517
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 121320, 121339, 121347, 65749
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 10731, 9745
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100102170, 100108906
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W08254001, W08254002, W08973001, W08973002
Country: SG	Health Sciences Authority	Identifier(s): 12190P, 15480P
Country: TN	Direction de la Pharmacie et du Médicament	Identifier(s): 5993082
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8699676950690, 8699676950706
Country: ZA	Health Products Regulatory Authority	Identifier(s): 35/21.1/0031